EDGE
Get a demo
Log In
All Updates

All Updates

icon
Filter
Product updates
Massive Bio launches Drug Utilization Optimizer at ASCO 2024
Clinical Trial Technology
Jun 1, 2024
This week:
Product updates
Stability AI launches Stable Diffusion 3 Medium, a text-to-image model
Foundation Models
Yesterday
Product updates
Microsoft discontinues GPT Builder in Copilot
Generative AI Applications
Yesterday
Funding
BlinqIO raises USD 5 million in funding to expand operations
Generative AI Applications
Yesterday
Product updates
Databricks launches innovations to Mosaic AI for production-quality applications
Generative AI Infrastructure
Yesterday
M&A
Rebellions and Sapeon Korea merge to challenge global AI chip leader
Generative AI Infrastructure
Yesterday
M&A
Pluxee to acquire Cobee; expands employee benefits offering
Remote Work Infrastructure
Yesterday
Product updates
Space and Time launches 'Proof of SQL' solution on GitHub
Enterprise Blockchain Solutions
Yesterday
Partnerships
Lido partners with Mellow Finance to launch liquid restaking vaults
Decentralized Finance (DeFi)
Yesterday
Funding
Rivia raises EUR 3 million in seed funding
Clinical Trial Technology
Yesterday
Product updates
Partnerships
Databricks and Shutterstock collaborate to launch enterprise-optimized ImageAI model
Generative AI Infrastructure
Yesterday
Clinical Trial Technology

Clinical Trial Technology

Jun 1, 2024

Massive Bio launches Drug Utilization Optimizer at ASCO 2024

Product updates

  • Massive Bio, a provider of AI-driven oncology solutions, announced the launch of its latest product, the "Drug Utilization Optimizer (DUO)," at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The DUO platform is developed to restructure how pharmaceutical commercial teams communicate with physicians and collect data.

  • DUO provides real-time insights, identifies key physicians conducting certain diagnostic testing at the local, regional, and country levels, and enhances brand revenues while minimizing sales costs. It also enables access to clinical and genomic data for precision targeting that goes beyond traditional data sources. Additionally, DUO helps promote testing for patients who need it and provides an industry-wide network of oncology experts.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.